Transforming medicine and changing lives
September 25, 2024
AskBio to collaborate with Belief BioMed to explore the potential of new gene therapiesAskBio and Belief BioMed will work together to advance potential gene therapies in diseases with high unmet medical need, using a liver-targeted approach Berlin, Germany, and Research Triangle Park, N.C., USA, September 25, 2024 – Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced a new strategic collaboration with Belief BioMed Inc. (BBM) to explore the potential for new gene therapies. Under the terms of the contract the companies will combine efforts and experience in gene therapy technology to explore potential therapies in diseases that may be treatable using a liver-targeted approach. “AskBio takes a collaborative approach when developing new gene therapies, and we look worldwide to use the most promising science to realize our goals,” said Mansuo Shannon, Chief Scientific Officer, AskBio. “The potential of BBM’s next-generation capsid technology, together with the work we are conducting at AskBio, is promising. We are looking forward to working closely with the team at BBM.” With global headquarters in Shanghai, China, BBM integrates the research and development, manufacturing, and clinical application of investigational gene therapy products for serious genetic and chronic diseases through viral vector technology. The company has developed advanced vector technologies and has established a commercial production platform for gene therapy drugs in China. In July, BBM announced that the New Drug Application (NDA) for its core product for hemophilia B was accepted by China National Medical Products Administration (NMPA), making this the first NDA submitted in China for a gene therapy product proposed for an inborn genetic disease.1 BBM has independently developed a variety of novel engineered adeno-associated virus (AAV) vectors; relative to conventional AAV vectors, the novel AAV vectors have shown reduced immunogenicity and robust transduction efficiency in human and non-human trials, respectively.2,3 “This strategic collaboration with BBM is an excellent example of how we work at AskBio and is particularly special given the extraordinary contributions Dr. Xiao has made to the field as BBM’s Chairman and Chief Scientific Officer and before as a co-founder of AskBio,” said Gustavo Pesquin, Chief Executive Officer, AskBio. “Collaborating with innovative, like-minded partners with complementary gene therapy expertise enables us to find the best way forward for our pipeline assets and bolster our efforts to advance new therapies for conditions with significant unmet need.” “Gene therapy has some of the greatest potential in modern medicine, particularly from a technical perspective,” said Juergen Eckhardt, MD, Head of Business Development & Licensing at Bayer Pharmaceuticals. “One path to success lies in collaborations such as this and in bringing together experts with broad expertise and experience. We are excited for AskBio’s new collaboration with BBM and the advancements it may one day bring to patients.” About AskBio Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, is a fully integrated gene therapy company dedicated to developing life-saving medicines and changing lives. The company maintains a portfolio of clinical programs across a range of neuromuscular, central ...read the news
We are on a never-ending quest to advance genetic technology
and life-saving AAV gene therapy
In 1984, Dr. Jude Samulski, one of AskBio’s visionary founders, asked if a virus could be used to erase genetic disease. Discovering the answer cleared the path for historic advances in genetic medicine, and AskBio is helping to lead the way.
Work with us
Advancing research
Today’s genetic discoveries are some of the most awe-inspiring advances in medical history. We welcome collaboration with innovative minds in genetic R&D.
Building careers
Help transform the face of healthcare with life-changing gene therapy. Every life enriched by our scientific advancements is a result of someone like you.